Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Business Wire 6 days ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Business Wire 10 days ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Business Wire 13 days ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Business Wire November 7, 2024

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Business Wire October 31, 2024

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

PR Newswire September 30, 2024

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Business Wire September 13, 2024

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Business Wire September 3, 2024

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Business Wire August 27, 2024

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Business Wire August 5, 2024

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Business Wire August 1, 2024

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Business Wire July 18, 2024

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Business Wire July 1, 2024

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Business Wire June 20, 2024

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

Business Wire June 7, 2024

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

Business Wire May 28, 2024

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

GlobeNewswire May 22, 2024

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Business Wire May 20, 2024

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Business Wire May 15, 2024

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Business Wire May 8, 2024